MedTrace Logo

Patient and Physician Knowledge of Key Safety Messages

NCT01907048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2227

Last updated 2021-04-08

No results posted yet for this study

Summary

This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

Conditions

  • Anticoagulation

Interventions

BEHAVIORAL

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

BEHAVIORAL

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure patient awareness and understanding of the key messages in the patient card.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • RTI Health Solutions

    collaborator OTHER

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-15
Primary Completion
2020-02-21
Completion
2020-04-15

Countries

  • France
  • Germany
  • Spain
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907048 on ClinicalTrials.gov